---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-007801"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:11:20.161940+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# KalVista reports preliminary Q4 EKTERLY revenue of ~$35M, full-year ~$49M; 1,318 patient start forms

## Summary
- Preliminary unaudited global net product revenue: ~$35M for Q4 2025, ~$49M for full year 2025.
- 1,318 patient start forms and 580 unique prescribers activated in the US through Dec 31, 2025.
- Prescription refills surpassed initial prescriptions as the primary revenue driver in Q4.
- Entered Latin America partnership with Multicare Pharma for Brazil, Argentina, Colombia, Mexico.
- Expect to file NDA for pediatric HAE patients (ages 2-11) in Q3 2026; US launch anticipated in 2027.

## SEC filing metadata
- accession: 0001193125-26-007801
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000119312526007801/0001193125-26-007801-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000119312526007801/d11988d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-007801
- JSON: https://secwatch.observer/filing/0001193125-26-007801.json
- Plain text: https://secwatch.observer/filing/0001193125-26-007801.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.